PROGENICS PHARMACEUTICALS IN's ticker is PGNX and the CUSIP is 743187106. A total of 154 filers reported holding PROGENICS PHARMACEUTICALS IN in Q4 2017. The put-call ratio across all filers is 1.56 and the average weighting 0.0%.
Quarter-by-quarter ownership
Value | Shares | Weighting | ||||
---|---|---|---|---|---|---|
Q1 2020 | $1,061,000 | -25.4% | 279,220 | -0.0% | 0.00% | 0.0% |
Q4 2019 | $1,422,000 | +7.9% | 279,303 | +7.1% | 0.00% | 0.0% |
Q3 2019 | $1,318,000 | -17.0% | 260,795 | +1.3% | 0.00% | -33.3% |
Q2 2019 | $1,588,000 | +42.2% | 257,328 | +6.9% | 0.00% | +50.0% |
Q1 2019 | $1,117,000 | +9.6% | 240,761 | -0.8% | 0.00% | 0.0% |
Q4 2018 | $1,019,000 | -17.6% | 242,734 | +23.1% | 0.00% | 0.0% |
Q3 2018 | $1,237,000 | -14.4% | 197,251 | +9.8% | 0.00% | -33.3% |
Q2 2018 | $1,445,000 | +17.7% | 179,714 | +9.2% | 0.00% | 0.0% |
Q1 2018 | $1,228,000 | +29.4% | 164,634 | +3.2% | 0.00% | +50.0% |
Q4 2017 | $949,000 | -7.1% | 159,560 | +15.0% | 0.00% | 0.0% |
Q3 2017 | $1,021,000 | +10.7% | 138,707 | +2.2% | 0.00% | 0.0% |
Q2 2017 | $922,000 | -28.1% | 135,737 | -0.0% | 0.00% | -33.3% |
Q1 2017 | $1,282,000 | +90.8% | 135,769 | +74.7% | 0.00% | +50.0% |
Q4 2016 | $672,000 | +44.5% | 77,727 | +5.7% | 0.00% | +100.0% |
Q3 2016 | $465,000 | +36.0% | 73,523 | -9.2% | 0.00% | 0.0% |
Q2 2016 | $342,000 | +12.5% | 80,988 | +16.1% | 0.00% | 0.0% |
Q1 2016 | $304,000 | -28.3% | 69,765 | +0.9% | 0.00% | 0.0% |
Q4 2015 | $424,000 | +14.6% | 69,130 | +6.8% | 0.00% | 0.0% |
Q3 2015 | $370,000 | -20.6% | 64,725 | +3.7% | 0.00% | 0.0% |
Q2 2015 | $466,000 | -12.7% | 62,403 | -30.1% | 0.00% | -50.0% |
Q1 2015 | $534,000 | -18.3% | 89,293 | +3.2% | 0.00% | 0.0% |
Q4 2014 | $654,000 | +58.0% | 86,493 | +8.4% | 0.00% | +100.0% |
Q3 2014 | $414,000 | +20.3% | 79,793 | 0.0% | 0.00% | 0.0% |
Q2 2014 | $344,000 | +62.3% | 79,793 | +53.8% | 0.00% | 0.0% |
Q1 2014 | $212,000 | -26.1% | 51,879 | -3.6% | 0.00% | 0.0% |
Q4 2013 | $287,000 | +5.9% | 53,789 | 0.0% | 0.00% | 0.0% |
Q3 2013 | $271,000 | +12.9% | 53,789 | +0.1% | 0.00% | 0.0% |
Q2 2013 | $240,000 | – | 53,717 | – | 0.00% | – |
Download |
Other shareholders
Name | Shares | Value | Weighting ↓ |
---|---|---|---|
Broadfin Capital, LLC | 8,951,169 | $54,871,000 | 3.38% |
Virtus ETF Advisers LLC | 103,807 | $636,000 | 1.75% |
BKS ADVISORS, LLC | 291,150 | $1,785,000 | 0.92% |
Piermont Capital Management Inc. | 363,549 | $2,229,000 | 0.71% |
TUDOR INVESTMENT CORP ET AL | 2,370,760 | $14,532,000 | 0.41% |
SEARLE & CO. | 60,000 | $349,000 | 0.34% |
TURNER INVESTMENTS LLC | 252,785 | $1,550,000 | 0.32% |
RICE HALL JAMES & ASSOCIATES, LLC | 891,672 | $5,466,000 | 0.31% |
Phocas Financial Corp. | 635,333 | $3,895,000 | 0.30% |
TFS CAPITAL LLC | 398,283 | $2,441,000 | 0.26% |